We are live on ! Find out more
REPL icon

Replimune Group

106 hedge funds and large institutions have $704M invested in Replimune Group in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 48 increasing their positions, 26 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 26

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

4% more funds holding

Funds holding: 102106 (+4)

1.15% more ownership

Funds ownership: 81.52%82.66% (+1.1%)

1% more capital invested

Capital invested by funds: $696M → $704M (+$7.51M)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

Holders
106
Holders Change
+4
Holders Change %
+3.92%
% of All Funds
1.83%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
12
Increased
48
Reduced
26
Closed
8
Calls
$2.75M
Puts
Net Calls
+$2.75M
Net Calls Change
+$417K

REPL Hedge Fund Activity: Q3 2022 in Review

106 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Replimune Group (REPL) for Q3 2022, worth a combined $704M — up 1.1% from $696M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new REPL positions and 8 closed out — a net gain of 4 holders — while 48 added to existing stakes and 26 trimmed.

The largest buyer was BlackRock, adding an estimated $8.43M. The largest seller was T. Rowe Price Associates, cutting an estimated $32.6M.

  • 106 institutional investors held Replimune Group (REPL) as of Q3 2022, up from 102 in Q2 2022.
  • Funds reported $704M of Replimune Group stock for Q3 2022, up 1.1% quarter-over-quarter.
  • 12 funds opened new Replimune Group positions in Q3 2022 and 8 closed out, a net change of +4 holders.
  • The largest Replimune Group buyer in Q3 2022 was BlackRock, an estimated $8.43M added.
  • The largest Replimune Group seller in Q3 2022 was T. Rowe Price Associates, an estimated $32.6M sold.

Based on aggregated 13F filings for Q3 2022.